Related resources
Full-text held externally
- PMID: 21929536
- UKPMCID: 21929536
- DOI: 10.1111/j.1365-2133.2011.10638.x
Search for item elsewhere
University researcher(s)
Academic department(s)
Practical experience of Ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.
Laws, P M; Downs, A M; Parslew, R; Dever, B; Smith, C H; Barker, J N; Moriarty, B; Murphy, R; Kirby, B; Burden, A D; McBride, S; Anstey, A V; O'Shea, S; Ralph, N; Buckley, C; Griffiths, C E M; Warren, R B
The British journal of dermatology. 2011;.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 21929536
- UKPMCID: 21929536
- DOI: 10.1111/j.1365-2133.2011.10638.x
Abstract
Background:  There are limited data on the use of ustekinumab outside of clinical trials. Objectives:  To assess the efficacy and safety of ustekinumab in patients with severe psoriasis attending 10 Dermatology Centres in the UK and Ireland. Methods:  A retrospective case-note review of 129 patients with psoriasis treated with ustekinumab. Results:  Baseline Psoriasis Area and Severity Index (PASI) was 22.9 ± 10.1 (mean ± SD). After 16 weeks' treatment with ustekinumab PASI 75 (75% reduction in PASI) was observed in 63.0% (n=80/127) of patients, although 4 patients required concomitant therapy at the 16 week time point. Previous use of systemic and biologic agents did not confer a tendency towards treatment failure. Individuals weighing 90-100kg and treated with the standard 45mg ustekinumab dose reached a PASI 75 response in 29.4% (n=5/17) compared to PASI 75 of 70.3%, 71.4%, 75.0% and 55.6% for weight groups <80kg, 80-90kg, 100-110kg and >110kg respectively (p=0.024). Ustekinumab therapy was well tolerated, serious adverse events were observed in 2.3% (n=3/129) of patients. Conclusions:  Ustekinumab is a novel biologic agent for psoriasis. When used in everyday clinical practice it demonstrates high levels of short-term therapeutic efficacy with an acceptable short-term safety profile.